Disruption Meets Risk: $HIMS Takes on $NVO/$LLY, $MGM Cuts Shares
$HIMS is shaking up the pharma space, challenging $NVO’s patents in a high-stakes bet that could disrupt the weight loss market.
Both $NVO and $LLY face significant downside risk if litigation goes against them, making this a fascinating clash between nimble disruptors and Big Pharma.
Meanwhile, $MGM is quietly reducing its float, repurchasing 5.5% of shares in a single quarter, signaling confidence amid broader market volatility.
Investors should watch legal battles and corporate capital moves alike for asymmetric opportunities.
1. $Hims & Hers Health Inc.(HIMS)$
My gut feeling is that $HIMS is playing the ultimate disruption card.
They’re pushing so hard Novo sues, which ultimately leads to Novo defending — and potentially invalidating — their patents.
We tend to take pharma patents at face value as a moat and some kind of validation of what Big Pharma has done.
In reality, patents are rarely challenged and most/many wouldn’t hold up in court.
I think Hims is betting Novo will either cave in a settlement or they go all the way to the finish line and blow up the weight loss business.
2. $Novo-Nordisk A/S(NVO)$ VS $Eli Lilly(LLY)$
$NOVO and $LLY have a LOT more to lose than $HIMS here.
That's what makes this situation so interesting. How much do you risk a $24 billion business with a 5-year half life if you're $NOVO?
3. $MGM Resorts International(MGM)$
MGM repurchased 15 million shares in the last 3 months.
Shares outstanding were 273 million on Oct 27, 2025.
That's a 5.5% reduction in shares outstanding in a single quarter!!!
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
